The cyclin-dependent kinase inhibitors known as p15, p16, p18 and p19 have been suggested as candidates for tumor suppressor genes. The main genetic alterations are deletions (bior monoallelic) or 5Ј CpG island methylation of p15 and p16; very few cases or cell lines had p18 or p19 deletions or hypermethylation. Hypermethylation and homozygous deletions of tumor suppressor genes establish a new paradigm of inactivation by lack of expression, in contrast to the previously identified tumor suppressors which are predominantly inactivated by point mutations followed by loss of the wild-type allele. Here, the literature data on alterations of this gene family in more than 4700 primary cases of leukemia or lymphoma and some 320 continuous leukemia-lymphoma cell lines are summarized. Among hematopoietic malignancies, the highest frequencies of p15 del and p16 del were seen in acute lymphoblastic leukemia (ALL) (Ͼ30%) with striking rates in T-ALL (Ͼ50%), but also high rates in B cell precursor (BCP)-ALL (Ͼ20%); the rates of deletions in chronic lymphoid leukemia (CLL), multiple myeloma, acute and chronic myeloid leukemia (AML and CML), and myelodysplastic syndromes (MDS) were rather low, only some B cell and T cell lymphomas showed increased frequencies. Results are quite different with regard to the second mode of inactivation, hypermethylation of the promoter region. Here, p15 is most often inactivated, at particularly high frequencies in the disorders lacking any p15/p16 deletions: 40-80% p15 met in AML, MDS and multiple myeloma. Also p15 met rates in BCPand T-ALL cases were high (c. 40%). There is controversy concerning the prognostic impact of p15 and p16 aberrations with some studies describing a significant correlation between inactivation of these genes and poor prognosis, while most others did not detect any prognostic relevance, at least in pediatric ALL; there may be a worse prognosis for adults with B or T cell lymphomas. Despite the small number of cases studied, paired sequential analyses suggested that disease progression is associated with loss of p15/p16 activity in a certain percentage of adult patients. p15 del /p16 del and p15 met /p16 met were also detected in the large panel of leukemia-lymphoma cell lines studied. In general, the results in cell lines reproduce the data seen in primary cells with the important difference that the rates of p15/p16 inactivation are clearly higher in the cultured cells compared with the freshly explanted cells. Retrovirus-or electroporation-mediated ectopic gene transfer of p16 wild-type into p16-deficient cell lines led to growth inhibition, arrest in G 1 (without apoptosis) and occasionally to differentiation, suggesting that the malignant phenotype of p16 −/− cell lines can, at least partially, be reversed by restoring p16 gene expression. A striking inverse correlation between the absence of p16 (due to deletion) and presence of wild-type retinoblastoma gene was observed in cell lines confirming a common growth suppressor pathway; no comparable relationship of p16 inactivation with p53 was detected. Paired analysis of cell lines and corresponding primary cell material showed that in all instances tested both populations carried the same gene configuration of p15 and p16. that p15 or p16 deletions already acquired in vivo provide a dramatic growth advantage for the immortalization process in vitro, thus increasing the success rate for cell line establishment which is commonly extremely difficult. In conclusion, the present review suggests an involvement of the p15 and p16 tumor suppressor genes in leukemo-and lymphomagenesis. Future studies will determine their exact role in the development and progression of hematopoietic neoplasms. These genes may represent interesting targets for new therapeutic strategies.
Introduction
Most genetic alterations that have been characterized in hematopoietic malignancies concern oncogene activation thought to contribute significantly and in a dominant manner to the transformed phenotype. Recently, however, a large body of evidence has suggested that the loss of tumor suppressor gene activity is an important event in the development of cancer. Since there are normally two functional copies of each autosomal gene per cell, tumorigenesis requires disruption of both copies of relevant tumor suppressor genes. 1 Inactivation of tumor suppressor genes occurs through a variety of mechanisms including point mutation, frameshift mutation, nondisjunction, deletion and other types of chromosomal alterations. Classical examples are the retinoblastoma gene Rb: here the primary mutational event involves a small genetic lesion such as a point mutation accompanied by the second event on the homologous chromosome which involves a greater change such as a deletion or whole chromosome loss. 2 Another common example is loss of heterozygosity of the p53 gene (the most frequently mutated tumor suppressor gene, in roughly 50% of all tumors) 3 paralleled by mutation of the remaining allele. 4 The observation that the human chromosome 9p21 region is a frequent site of deletions and rearrangements in many tumor types including leukemias 5 implied the existence of a tumor suppressor gene within 9p21 which is involved in tumor formation. The type-I interferon gene cluster maps to 9p21-22 and was originally suggested as the target for deletions in leukemias, 6 but was instead later considered to be an innocent bystander being deleted because of its close genomic proximity to other genes. 7 Later, the gene p16 INK4A was identified in this region and was found to possess many features suggesting that it is a gene relevant to loss of heterozygosity at this site. 8, 9 p16 INK4A is also termed MTS1 for 'multiple tumor suppressor 1' or CDK4I for 'cyclin-dependent kinase 4 inhibitor' -the official HUGO nomenclature is CDKN2, however, the acronym p16 is still much more widely used and will also be applied here.
Progression of eukaryocytic cells through the cell cycle is 846 regulated by the sequential formation, activation and subsequent inactivation of a series of structurally related serine/threonine kinases. These enzymes consist of a catalytic unit, a cyclin-dependent kinase (CDK), and a regulatory unit, a cyclin. 10 The enzymatic activity of a CDK is regulated at three different levels: cyclin binding and activation, subunit phosphorylation, and association with and inhibition by a group of heterologous small regulatory proteins, the so-called CDK inhibitors. The p16 gene encodes such a protein which was previously described as an inhibitor for CDK4 or CDK6. 11 The detailed roles of cyclins, CDKs and CDK inhibitors in the cell cycle have been reviewed elsewhere. 12 Suffice it to say that CDK inhibitors can block cell cycle progression by effectively inhibiting the kinase activity of CDKs, and they therefore exert a negative control on cell proliferation.
p16 was found to be homozygously deleted at high frequency in cell lines derived from a wide range of tumor types (47%); small genetic lesions, above all point mutations, were seen at much lower frequency (8% of the same group of cell lines) than the homozygous deletion. 13 It was proposed that homozygous deletion is the predominant mechanism for inactivating p16 in most tumor cell lines, including leukemia-lymphoma cell lines. 13 p16 was the first example of a tumor suppressor gene which is inactivated most frequently by two deletion events, one on each homolog; for comparison, homozygous deletion accounts for less than 5% of the mutation events in p53. 4, 13 Among the components of the cell cycle machinery, p16 is by far the most frequently altered gene in cancer. 12 As the mutation rate in primary solid tumors was subsequently found to be much lower than in cancer cell lines, it was argued, albeit without any scientific evidence to support this contention, that some p16 deletions/mutations may have occurred during growth in culture (because cell lines have been propagated for many generations in vitro thus undergoing more cell divisions than primary tumor cells); alternatively, tumor cells with p16 homozygous losses may have a selective growth advantage in tissue culture. 14 The high frequency of p16 deletions in many types of tumors suggested that this gene is a major tumor suppressor gene, 15 a conclusion that has recently been reinforced by analysis of knockout mice lacking functional p16 genes which facilitated spontaneous B cell lymphoma development. 16 Another gene, termed p15 INKB (or MTS2), with high homology to p16 is located in the same chromosomal region. 8 The p15 protein is a transforming growth factor-␤ (TGF-␤)-induced inhibitor of CDK4 and CDK6. 17 Subsequently, two further specific polypeptide inhibitors of CDK4 and CDK6 proteins, termed p18 (located on chromosome 1p32) and p19 (on chromosome 19p13), inducing G1 arrest have been discovered; thus altogether four proteins, p15 INK4B   , p16  INK4A , p18  INK4C and  p19 INK4D forming the so-called INK4 family, have been identified. [18] [19] [20] [21] Protein sequence homology discriminates the INK4 family from another class of CDK inhibitors, the latter class comprising p21 WAF1 , p27 KIP1 and p57
KIP2
. 22 Immediately following the discovery of p15 and p16 deletions in tumor cells, several early reports also documented a high frequency of homozygous deletions of p15 and p16 also in acute lymphoblastic leukemia (ALL), especially in leukemias of the T cell lineage. [23] [24] [25] It quickly became clear that loss of wild-type p15/p16 function is probably one of the most common genetic aberrations in ALL and is now thought to play a key role in leukemogenesis. [26] [27] [28] [29] The notion, initially based on data obtained from studies on solid tumor cell lines, that homozygous deletion may be the primary mode of inactivation of p16, also applies to leukemias and lymphomas as point mutations were only demonstrated in a few cases. 12, 30 Deletions/rearrangements of these tumor suppressor genes are commonly detected by Southern blotting, polymerase chain reaction (PCR), or fluorescence in situ hybridization (FISH); mutations are examined by single strand conformation polymorphism and defined by direct sequencing. Analysis of fresh tumor samples can be a challenging task, particularly when using PCR, as 'contamination' with residual normal cells may override the possibly negative signals from the p15/p16-deleted neoplastic cells. FISH has the advantage of identifying deletions in subpopulations of cells and at the single cell level. 31, 32 For technical reasons, hemizygous deletions are also difficult to detect by Southern blotting or PCR in tumor samples contaminated with up to 20% of normal residual cells. Also of note are reports where p15 and p16 deletions were seen without 9p cytogenetic deletions. 26 In most cases (greater than two-thirds of the patients) with p16 deletions, its homologous neighbor p15 is also altered; however, the overall higher incidence of p16 deletions over p15 is consistent with the notion that p16 rather than p15 is the target of the deletion on 9p21 in leukemia-lymphoma. [33] [34] [35] The detailed analysis over the last 3-4 years on the inactivation of these genes in large panels of primary cells and the increasing use of continuous leukemia-lymphoma cell lines with alterations of INK4 genes has prompted this review. While some data on p18 and p19 have been reported, the bulk of information concerns p15 and p16. The questions to be addressed in this review include the following: (1) What is the incidence of p15/p16 gene deletions in human malignant hematopoietic cells in both primary material and in continuous cell lines, in direct comparison and related to the corresponding hematopoietic cell lineages? (2) What is the incidence of another common form of p15/p16 gene inactivation, namely hypermethylation? (3) Do these p15/p16 gene deletions have any prognostic significance and is there a correlation between the p15/p16 gene status and disease progression or transformation? (4) Is there any relationship between the status of the p15/p16 genes and the configuration of the p53 and Rb genes? (5) Is there evidence for or against the assumption that these genetic alterations in leukemia-lymphoma cell lines represent in vitro artefacts acquired during initiation of the lines or prolonged culture?
Frequency of p15, p16, p18 and p19 deletions in hematopoietic disorders Tables 1 and 2 summarize the data on p15, p16, p18 and p19 deletions in the various categories of hematopoietic malignancies. First of all, there are hardly any deletions of p18 and p19 throughout the panel of diseases. Secondly, there are clearcut differences between the lymphoid and myeloid neoplasms. Except for CML in lymphoid blast crisis (which behaves in this regard like a BCP-ALL), only few cases of AML, CML or MDS with p15 or p16 deletions were described. LGL, large granular lymphocyte leukemia; LPD, lymphoproliferative disorder; MALT, mucosa-associated lymphoid tissue lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndromes; met, methylated; MF, mycosis fungoides; MM, multiple myeloma; NHL, non-Hodgkin's lymphoma; PCL, plasma cell leukemia; Ph, Philadelphia chromosome; PLL, prolymphocytic leukemia; pm, point mutation; PTCL, peripheral T cell lymphoma; PV, polycythemia vera; R, rearrangement; RA, refractory anemia; RAEB, refractory anemia with excess of blasts; RAEB-T, refractory anemia with excess of blasts in transformation; RARS, refractory anemia with ring sideroblasts; SLL, small lymphocytic lymphoma; SLVL, splenic lymphoma with villous lymphocytes; SS, Sé zary syndrome; T, T lymphocyte; T-LL, T lymphoblastic lymphoma; wt, wild-type. The number of deletions is also low in multiple myeloma and plasma cell leukemia. Clearly the majority of specimens with p15 and p16 deletions were seen in ALL and the various mature B cell or T cell lymphoproliferative disorders. Rates are low in typical chronic leukemias such as B-CLL/PLL, HCL and T-CLL/PLL, but somewhat higher in B or T cell lymphomas, eg ATLL, DLCL and MCL. The absolute highest frequency of these deletions were detected in ALL (Ͼ30%) with T-ALL representing the leukemia that is most often affected (Ͼ50%).
Regarding the comparison of pediatric vs adult cases, data are available for BCP-ALL, T-ALL and total ALL (Figure 1 ). In all three of these categories, the percentages of children with p15 del or p16 del were always higher than the respective figures for adults. Only one study reported on infants with ALL (subtyping was not given); here, all 74 cases analyzed were negative for p15 and p16 deletions.
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Hypermethylation as an alternative mode of p15 and p16 inactivation
Taken together, the first studies showed that: (1) point mutations of p15 and p16 occur very infrequently in leukemias and lymphomas; and (2) homozygous deletion is one of the primary mechanisms of inactivation. However, another Homozygous and heterozygous deletions of p15 and p16 are combined.
Figure 1
Comparison of the frequency of p15/p16 deletions in primary acute lymphoblastic leukemia cases among children, adults and infants. Compilation of literature data (for references see Table 1 ). Results on infants were reported only for ALL in one series (not specified for subtypes).
mode of gene inactivation, hypermethylation of CpG islands, was also found to occur in a large percentage of cases. CpG islands are regions of DNA, typically 0.5-2.0 kb in length. They are GC rich, contain the normally underrepresented CpG dinucleotide at the expected frequency, and remain unmethylated in normal tissues when found in the 5Ј region of genes. Hypermethylation of normally unmethylated CpG islands in the promoter regions of tumor suppressor genes (including p15 and p16) correlated with loss of transcription, suggesting an alternative mechanism to intragenic (coding region) mutations or deletions for tumor suppressor gene inactivation. [103] [104] [105] [106] Normal cells had no detectable promoter region methylation of p15 and p16. 42, 104, 106 Hypermethylation of p15 and p16 has been studied in a number of leukemia and lymphoma cases producing unexpected results (Table 3 ). Hypermethylation of p15 was an almost universal finding in AML and also occurred very frequently in MDS and ALL; methylation of p16 in AML, MDS and ALL was a rare event. In contrast, neither p15 nor p16 were inactivated in any stage of CML. Hypermethylation of p16, usually with lower rates of alteration than p15, was found in mature B lymphoproliferative disorders. Similar to AML and MDS where p15/p16 inactivation is not achieved by homozygous deletion, p15/p16 alterations in multiple myeloma are solely caused by hypermethylation (in this instance of both p15 and p16).
Thus it appears that hypermethylation of p15 and p16 is a selective phenomenon which is dependent on tumor type. Furthermore, this alternative mode of p15 and p16 inactivation significantly increases the number of the cases in which these genes are altered; for instance, the overall rates of alter- Table 3 Frequency of methylation of p15 and p16 genes in hematopoietic malignancies (summary of literature review) 61 These data demonstrate that by examining both homozygous deletions and hypermethylation as inactivating events, important selective roles for p15 and p16 can be defined for subtypes of hematological malignancies, and that both genes are virtually always involved.
Prognostic relevance of p15 and p16 alterations
Data in the literature are contradictory regarding the clinical significance of p15 and p16 deletions (Table 4) . Six studies on children with ALL have been reported, two of which described a worse prognosis of patients with p16 del (and p15 del ) 45, 106 ; four other series did not detect any statistically significant difference between these patients. 34, 35, 48, 54, 55 In adults, one study on ALL failed to document any prognostic value for p16 deletion. 57 Two further studies on ATL and B-NHL described a worse prognosis for adults with p15 del /p16
del than for cases in the p15 wt /p16 wt groups. 39, 90 A separate set of data correlates the events of disease progression (for instance patients at diagnosis vs patients at relapse) and transformation (eg from MDS to overt leukemia) ( Table 5 ). Two types of analyses were reported: comparison of unpaired cohorts where, for example, patients of cohort 1 examined at diagnosis were different from the patients of cohort 2 investigated at relapse. The second form of investigation concerned paired sequential analysis of the same patient, for instance in the chronic phase of ATL vs its acute phase (Table 5 ). Again the results are mixed with regard to the 850 del (n = 24) compared with p16 wt (n = 16) regarding post-relapse survival.
Table 5
Correlation of disease progression or transformation with the p15/p16 status (summary of literature review) del and p15 met /p16 met when comparing cohorts of children at diagnosis with patients at relapse. 35, 48, 61 In adults, higher frequencies of p16 deletion were published for patients with aggressive or high-grade B-NHL vs cases with indolent or low-grade variants of these disorders. 66, 79 Definitely fewer patients were examined in the paired sequential analysis encompassing children with BCP-ALL, T-ALL and CML and adults with ALL, mature T and B cell lymphoid disorders and MDS (Table 5) . Again, in children the rate of a change of p15 wt /p16 wt to p15 del /p16 del or to p15 met does not seem to accompany the progression/transformation of disease as often as in adults: in children in 0-33% of ALL; in adults in 33-71% of ALL, ATL and MDS. However, it is obviously difficult to compare the various disease categories in this type of analysis, particularly as only small numbers of patients have been examined in this regard.
Deletion and hypermethylation of p15 and p16 in leukemia-lymphoma cell lines
The two initial studies that first recognized the possible involvement of p15 and p16 in tumorigenesis, subsequently also drawing the attention of hematological researchers to this field, were performed using large panels of continuous cell lines (n = 290 and n = 46) encompassing a large variety of tumor types. 8, 9 The basis for the particular interest of hematologists in these unique tumor suppressor genes was the fact that 1/4 and 9/14 leukemia cell lines were described as harboring p16 deletions; however, no specific details concerning name of cell lines, cell lineage or immunophenotype were presented. 8, 9 Over the last 4 years, the gene status of p15, p16, p18 and p19 of some 324 hematopoietic cell lines have been analyzed (Table 6) .
Similar to the literature on primary cases, fewer cell lines have been studied with regard to p18 and p19 deletions and nearly all of those examined were found to be negative; thus, in both primary cases and cell lines, p18 del and p19 del are rare events, if they occur at all (Table 6 ). While all EBV + B lymphoblastoid cell lines, representing normal hematopoietic cells, have p15 and p16 wild-type gene configurations, high percentages of p15 del and p16 del were found in B and T cell lineage lines, with the highest rates in the subtypes BCP cell lines and immature T cell lines, corresponding to the primary BCP-ALL and T-ALL, respectively. In contrast to the data obtained in patients, 27% and 29% of the myeloid cell lines studied carry p15 and p16 deletions, respectively. Table 7 provides a list of the most widely used cell lines and their p15 and p16 gene status.
Hypermethylation of p15 and p16 also occurs in cell lines; however, only a few lines have been tested in this regard. The results of all cell lines reported thus far are presented in Table 7 . Data from a larger panel of cell lines are required before any definitive conclusions can be drawn.
Correlation of p16 deletions with alterations of p53 and Rb genes
The above mentioned retinoblastoma susceptibility gene Rb is also a key player among the cell cycle-regulatory proteins. 135, 136 Physiological inactivation of its growth-suppressive properties is thought to occur by CDK4/CDK6-mediated phosphorylation of Rb which, in turn, is stimulated by cyclin D1. 12 Unregulated phosphorylation of Rb by CDKs, for instance, due to the lack of the CDK inhibiting activity of proteins like p15 and p16 or in response to overexpressed cyclin D1, could lead to loss of growth control. Based on this reasoning, Rb-positive tumors might overexpress cyclin D1 and/or CDK4/6, thus leading to inactivation of Rb, while Rb-negative tumors might not require cyclin D1-/CDKs overexpression (and thus p15/p16 deletion).
This reciprocal Rb inactivation and p16 expression and vice versa was indeed detected in several series of solid tumor cell lines. 133, 137, 138 Summarizing the data on the p16 and Rb status in leukemia-lymphoma cell lines, the resulting picture confirms the predicted reciprocity between p16 inactivation and Rb expression also in the hematopoietic cell lines (Figure 2) . One may argue that no further growth advantage would be gained by a tumor cell if p16 del and Rb pt would occur concurrently. It should, however, be noted that significantly fewer Rb data were available for the present review than information on the p16 gene status in cell lines; this might have led to a certain bias with regard to the predominance of the p16 del + Rb wt combination to the disadvantage of the other possibilities. Still, no such inverse correlation was found for p16 del and p53 alterations ( Figure 2 ). Systematic studies on cell lines and primary cells need to be performed to verify whether aberrations of the upstream components of the cell cycle regulatory pathway (such as cyclin D1 and p16) alterations of Rb occur in a strictly reciprocal manner.
Because alterations of p16 and p53 often occurred in the same solid tumor cell lines, in contrast to mutually exclusive aberrations of p16 and Rb, it was suggested that the products of p16 and p53 tumor suppressor genes function in distinct pathways. 138 From the data available in the literature, it is not (yet) possible to extrapolate this hypothesis to leukemia-lymphoma cell lines. Furthermore, cell lines lacking both Rb and p16 and other lines devoid of both p16 and p53 have been described (Figure 2) . While a correlation between p16 inactivation and wild-type Rb was also described for primary lymphoid malignancies, no correlation was found for p16 and p53. 68, 85, 131, 139 Functional studies: ectopic p16 expression in p16-deleted cells As loss of the p16 gene is presumed to play a role in the unlimited proliferation of neoplastic cells, re-expression of p16 should theoretically lead to growth inhibition. Indeed, restoration of p16 expression in p16-deficient solid tumor cell lines or overexpression of p18 resulted in a dramatic reduction of growth and malignant phenotype. 18, 130 To test the hypothesis that p16 suppresses the growth of p16 del leukemias, six studies utilized retroviral systems or electroporation to reestablish p16 wild-type expression (Table 8) .
A number of cell lines, originally lacking the p16 gene due to homozygous deletion, were successfully transfected with wild-type or mutant p16. In most cell lines, the transformed phenotype was reverted and growth was partially or completely inhibited; cells became arrested in the G 1 phase; pRb was dephosphorylated; cellular differentiation was induced; but only wild-type and not mutant p16 genes were effective (Table 8 ). This approach worked well in seven different cell lines, but not in CCRF-HSB-2 and HL-60. Growth of the immature T cell line CCRF-HSB-2 that lacks both p16 and Rb 
Figure 2
Correlation of p16 deletions with alterations of the p53 and Rb genes in cell lines. Shown are the number of cell lines with alterations of the three genes as reported in the literature. Note that a p16 deletion is most often associated with a wild-type Rb gene (n = 22), whereas the combinations of alterations and wild-type p16 and p53 are nearly equally distributed.
Table 8
Effects of ectopic p16 expression in p16-deficient leukemia-lymphoma cell lines (summary of literature review)
Ref.
Cell line (cell type) Effects was not inhibited, indicating that growth suppression involves the pRb pathway. 130 The inefficient inhibition of HL-60 proliferation post-p16 wt transfer remains unexplained. It should be noted that most studies reported a heterozygous p16 deletion for HL-60 accompanied by a p16 point mutation, whereas others did not find any p16 deletion in HL-60 at all. Still, the above results provide strong evidence for the possibility of restoring p16 expression in p16-deleted cells by gene transfer leading to subsequent growth inhibition. A recent study documented that enforced overexpression of p19 and the resulting inhibition of CDK activity in the murine myeloid growth factor-dependent cell line 32D not only blocked G 1 phase progression, but also prolonged cell survival in the absence of supportive growth factors and induced features of differentiation in the presence of IL-3. 
in vitro artefacts
The differences in the rates of p15 del and p16 del between primary material and continuous cell lines are best appreciated in a graphical summary (Figure 3) . In nearly all categories, the frequencies of p15 del and p16 del are clearly higher in cell lines than in primary cases. If the Burkitt cell lines are excluded from the analysis (almost all Burkitt cell lines have, surpris-
Figure 3
Comparison of the frequency of p15/p16 deletions in primary leukemia-lymphoma cases vs the respective cell lines. Compilation of literature data (for Refs see Tables 1, 2 and 6 ). The categories for the cell lines correspond to those listed in Table 6 ; the categories for the primary cases correspond to those shown in Table 1 as follows: BCP, BCP-ALL; immature B cell, B-ALL/Burkitt; mature B cell, mature B-LPD; plasma cell, plasma cell dyscrasias; immature T cell, T-ALL/T-LL; mature T cell, mature T-LPD; myelocytic, AML M1-M2; monocytic, AML M4/M5; erythroid-megakaryocytic, AML M6/M7. Note the significantly higher frequency of p15 del and p16 del in nearly all cell line categories; except for the category 'immature B cell' where the generally p15 del /p16 del -negative Burkitt cell lines (0/7 p15 del ; 1/47 p16 del ) significantly decrease the percentages (B-ALL cell lines alone: 2/3 p15 del ; 4/9 p16 del ).
Table 9
Concordance of p16 gene configuration between primary material and resulting cell line (summary of literature review) ingly, a p15/p16 wild-type), then all cell line categories display higher frequencies in p15/p16 deletions than their respective in vivo counterparts. The discordance is particularly striking between myeloid cell lines and AML where, the various cell types taken together, 27% p15 del and 29% p16 del in cell lines vs 1% and 2% in fresh cells were found, respectively.
These discrepancies led some investigators to conclude that the deletions were acquired during establishment of the cell lines or during extended in vitro culture. 28, 97, 99, 129 However, no data were forthcoming to support this contention. Others felt that an alternative possibility should be entertained, namely that this sort of 'molecular disability' of a malignant cell may favor its immortalization; in other words, it may be easier to establish cell lines from tumors which suffered mutations of their p15/p16 genes during their development in vivo. 33, 128, 144 In this context, it is noteworthy that the establishment of leukemia-lymphoma cell lines still represents a rather difficult exercise with a decidedly low success rate that lies in the range of 1-10%, depending on the type of malignant cell. 145, 146 Certainly, the original primary cells must possess some features that make them amenable for immortalization in vitro in contrast to the majority of samples where this endeavour fails. It might well be that a p15 and/or p16 deletion could render the cells susceptible for cell culture, raising the chances of establishing a cell line and also leading to a selection of cases with p15 del /p16 del . On the other hand, obviously not all cell lines carry a p15 or p16 alteration (Table 6 ).
The only way to resolve the issue is to perform a paired analysis, ie investigating the p16 gene configuration in both the cell line and the primary cell material from which the cell line was derived (Table 9) . Using this approach, 36 leukemialymphoma cell lines and the paired original cells were examined. 58, [117] [118] [119] [120] [121] In all 36 pairs, cell line and primary material showed the same p16 gene configuration; in particular, the alleged sequence of p16 wt → p16 del from in vivo cells to the in vitro cells was never found.
These data provide unequivocal evidence that the differences in the p15 del /p16 del frequencies are not caused by genetic instability of the cell lines in continuous culture, but are probably due to the selective establishment of cell lines from patients with these genetic alterations, possibly in combination with other known or unknown aberrations. However, one caveat is the fact that the paired cell line-original cells analysis has not yet been performed on myeloid leukemia lines and their primary cell material (this work is currently in progress). Finally, should p15 and p16 deletions occur during extensive culture in vitro, then one would expect a much higher frequency of these alterations, as the majority of the 'older' leukemia cell lines have been in culture for several years and have all, as a rule, aneuploid karyotypes. In fact, many 'old' cell lines retained the p16 gene in culture over many years, suggesting that deletions of p16 do not arise frequently as an artefact of cell culture. 121 With regard to methylation, exactly the same pattern of 5Ј CpG island methylation was found in cultured and primary tumors, but not in corresponding normal tissues, arguing that this specific form of methylation is a manifestation of the neoplastic transformation and not merely due to expansion of CpG methylation during cell culture. 103 While this molecular genetic argument has not yet been shown for leukemia cell lines, such data are available from other tumor cell lines.
Conclusions
The malignant transformation of tumor cells is known to be driven by the accumulation of various genetic alterations, some of them made visible by numerical and structural chromosomal aberrations, others only detectable by molecular genetic methods. Among the specific alterations associated Table 10 Synopsis of salient data on p15 and p16 alterations in hematopoietic malignancies ¼ Highest frequency of p15 del /p16 del (Ͼ30%) in ALL: T-ALL (Ͼ50%), BCP-ALL (Ͼ20%); low frequency of p15 del /p16 del (0-4%) in multiple myeloma and mature T or B lymphoproliferative disorders (except some B-NHL and ATLL); very low frequency of p15 del /p16 del (0-1%) in AML, CML, MDS.
¼ High rate of p15 met in AML (Ͼ70%), multiple myeloma (Ͼ60%, MDS (Ͼ40%), BCP-and T-ALL (40%); p16 usually not methylated.
¼
Probably no prognostic significance of p15 del /p16 del for children with ALL; possible prognostic significance for adults with T/B cell lymphomas; correlation of molecular changes of p15/p16 with disease progression/transformation in some cases. with neoplasms, the loss of tumor suppressor genes has been recognized as an important element. However, deletions or mutations of the two most commonly inactivated tumor suppressor genes, p53 and Rb, have been detected only in a minority of patients with leukemia or lymphoma. 4, 147 In comparison to other genetic abnormalities characterizing human hematopoietic malignancies such as hybrid fusion genes, 148 lesions affecting tumor suppressor genes are usually less consistent and less specific, ie they are found at low frequency and in various tumor subsets. There is an interesting diversity in the mode of inactivation of tumor suppressor genes. The p15 and p16 genes are usually homozygously deleted or hypermethylated, whereas the p53 and Rb genes often have a point mutation of one allele with loss of the normal allele.
All studies, both on in vivo and on in vitro neoplastic hematopoietic cells, document that p15 and p16 deletions are predominantly associated with malignancies of immature lymphocytes, foremost among them is T-ALL followed closely by BCP-ALL. Other hematopoietic disorders also showed p15 del and p16
del , but the frequencies are generally low. The tumor cells of some of the hematopoietic disorders that are not afflicted by p15/p16 deletions display the second major option of p15/p16 gene inactivation, namely hypermethylation, which is seen at strikingly high levels in AML, MDS and multiple myelomas, but also in ALL adding to the already high rates of p15/p16-deleted cases. Thus, irrespective of whether via deletion or via hypermethylation, loss of wild-type p15/p16 function may be one of the most common genetic aberrations in several types of leukemia.
With regard to the striking differences in p15 del /p16 del between cell lines and primary cells, there are two plausible explanations: (1) p15/p16 inactivation provides a selective growth advantage (a cause or precondition for cell immortalization); (2) after immortalization, cell lines may become prone to deletion of this locus (a result of cell immortalization). 24 Clearly the first explanation applies here as there is no published evidence for p16 −/− cell lines which were derived from p16 +/+ primary tumors. Concerning the clinical significance, p15/p16 alterations might indeed be one of the earliest, clonally selected genetic changes during tumorigenesis. The development of diagnostic assays for molecular screening might best be based on the absence of the gene product rather than on the (technically more difficult) detection of structural alterations of the gene (eg immunohistochemical protein staining or FISH). 103 With regard to the prognostic significance of these gene alterations, the verdict is not unanimously in; the currently available evi-dence tends to suggest: (1) that there is no prognostic impact of these gene aberrations for children with ALL; but (2) that there might be prognostic relevance for adults with B or T cell lymphomas; and (3) that, at least in some cases, homozygous p15/p16 deletions or hypermethylation may play an as yet undefined role in disease progression or transformation.
Following the results of the experiments using ectopic expression of these CDK inhibitors in previously deficient cells, p15 and p16 have become obvious targets for future biological therapies. New therapeutic strategies can be developed based on re-expression of the gene product in deficient cells either pharmacologically or by a targeted gene delivery approach. 103 A synopsis of the data presented in this review is given in Table 10 . Taken together, the extensive work of the last 3-4 years has provided overwhelming evidence supporting an important involvement of the p15 and p16 tumor suppressor genes in leukemo-and lymphomagenesis. Further studies are needed to determine their exact role in the development and progression of hematopoietic neoplasms.
